Literature DB >> 32419031

A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis.

Chan Ho Na1, Wenelia Baghoomian, Eric L Simpson.   

Abstract

Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease that is characterized by complex immune dysregulation and skin barrier dysfunction with a wide variety of clinical phenotypes. Until recently, conventional therapeutic modalities for AD remained rather non-specific despite AD's complex etiology. Failing to take into account the underlying inflammatory pathways led to treatments with inadequate efficacy or unacceptable long-term toxicities. We are currently in the midst of a therapeutic renaissance in AD. Recent progress in molecular medicine provides us a better understanding of the AD pathogenesis, suggesting a dominant helper T cell (Th) 2/Th22 response with a varying degree of Th1/Th17 overexpression. Targeted therapeutic agents including biologics and small molecule inhibitors in development hold promises for more effective and safer therapeutic approaches for AD. A better understanding of individual differences amongst AD patients will allow for a more tailored approach in the future. This review aims to cover the most promising emerging therapies in the field of atopic dermatitis utilizing recently published manuscripts and up-to-date conference abstracts and presentations.

Entities:  

Keywords:  biologics; small molecule inhibitors; targeted therapeutic agents; atopic dermatitis

Mesh:

Substances:

Year:  2020        PMID: 32419031      PMCID: PMC9189747          DOI: 10.2340/00015555-3515

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  113 in total

1.  Treatment of severe refractory adult atopic dermatitis with ustekinumab.

Authors:  Rafael Puya; Maria Alvarez-López; Antonio Velez; Enrique Casas Asuncion; José Carlos Moreno
Journal:  Int J Dermatol       Date:  2012-01       Impact factor: 2.736

Review 2.  Emerging therapies for atopic dermatitis: JAK inhibitors.

Authors:  David G Cotter; David Schairer; Lawrence Eichenfield
Journal:  J Am Acad Dermatol       Date:  2017-12-15       Impact factor: 11.527

3.  Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.

Authors:  Andreas Wollenberg; Michael D Howell; Emma Guttman-Yassky; Jonathan I Silverberg; Christopher Kell; Koustubh Ranade; Rachel Moate; René van der Merwe
Journal:  J Allergy Clin Immunol       Date:  2018-06-12       Impact factor: 10.793

4.  The histamine H4 receptor is functionally expressed on T(H)2 cells.

Authors:  Ralf Gutzmer; Susanne Mommert; Maria Gschwandtner; Katja Zwingmann; Holger Stark; Thomas Werfel
Journal:  J Allergy Clin Immunol       Date:  2009-03       Impact factor: 10.793

5.  Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis.

Authors:  M Toyoda; M Nakamura; T Makino; T Hino; M Kagoura; M Morohashi
Journal:  Br J Dermatol       Date:  2002-07       Impact factor: 9.302

6.  Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.

Authors:  Ellen H van den Bogaard; Judith G M Bergboer; Mieke Vonk-Bergers; Ivonne M J J van Vlijmen-Willems; Stanleyson V Hato; Pieter G M van der Valk; Jens Michael Schröder; Irma Joosten; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

7.  Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors:  Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

8.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

9.  Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Authors:  Emma Guttman-Yassky; Patrick M Brunner; Avidan U Neumann; Saakshi Khattri; Ana B Pavel; Kunal Malik; Giselle K Singer; Danielle Baum; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sharon Rose; Shelbi Jim On; Xuan Li; Judilyn Fuentes-Duculan; Yeriel Estrada; Sandra Garcet; Claudia Traidl-Hoffmann; James G Krueger; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2018-01-17       Impact factor: 11.527

Review 10.  Keratinocytes in atopic dermatitis: inflammatory signals.

Authors:  Clemens Esche; Anna de Benedetto; Lisa A Beck
Journal:  Curr Allergy Asthma Rep       Date:  2004-07       Impact factor: 4.919

View more
  1 in total

Review 1.  New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature.

Authors:  Nikolaos Sideris; Eleni Paschou; Katerina Bakirtzi; Dimitra Kiritsi; Ilias Papadimitriou; Aikaterini Tsentemeidou; Elena Sotiriou; Efstratios Vakirlis
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.